Erythema multiforme


Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports

Erythema multiforme (EM) is a distinct cutaneous reaction pattern to a variety of stimuli, predominantly herpes simplex virus (HSV) infection, occurring mostly in young adults. It usually runs a self-limiting course but has a tendency to recur. It is defined by the presence of ‘typical’ three-zone target lesions, with a usual acral distribution. The presence of mucosal involvement at more than one site distinguishes EM major from EM minor. A specific variant has mucosal lesions only, without skin involvement. EM major can be distinguished from Stevens–Johnson syndrome, which lacks typical targetoid lesions and an acral location, but rather presents with irregular macules or atypical targets and a truncal location; regardless, these two diseases are still frequently confused. EM is frequently misdiagnosed as other entities such as urticarial dermatoses and, more rarely, in cases of cutaneous lupus, vasculitis, erythema annulare, and drug eruptions. Paraneoplastic pemphigus may mimic EM major.

Management Strategy

In 30%–50% of cases the etiology of EM is unknown. The most commonly recognized precipitant is HSV infection; both types I and II HSV-specific DNA has been isolated from lesional tissue in 60%–70% of cases. HSV particles are found in the circulating precursors of epidermal Langerhans cells. A variety of other viral infections (orf, varicella zoster virus [VZV], Epstein–Barr virus [EBV], cytomegalovirus [CMV], human immunodeficiency virus [HIV], hepatitis B vaccination), bacterial infections (mainly Mycoplasma pneumoniae but also tularemia), and fungal infections (predominantly histoplasmosis) have been implicated. An extensive list of drugs has been reported to trigger EM, but most cases, if not all, are the result of confusion with Stevens–Johnson syndrome. Rare cases may be attributed to contact allergy.

Acute episodes of EM need only symptomatic treatment in most cases. Recurrent EM, which may severely affect quality of life, has a well-recognized preventive treatment in case of HSV infection but may be highly recalcitrant when no cause is identified. A persistent continuous variety of EM has been reported with antidesmoplakin antibodies, which do not testify pemphigus.

There are no double-blind or open trials of treatments for acute episodes of EM. Most cases, particularly EM minor, run a self-limiting course. Symptomatic measures include oral antihistamines and mild-to-moderate-potency to reduce pruritus. Underlying conditions, mainly Mycoplasma pneumoniae infection, should be treated. Recurrent EM (>6 attacks per year) may respond to long-term anti-HSV drugs . In resistant cases a variety of other therapies can be helpful (see later).

Mucosal manifestations of EM major are a source of morbidity. The most common sites affected are the buccal mucosa and lips. Symptomatic measures include mouthwashes, a soft diet , topical anesthetics , and topical corticosteroids (e.g., 0.1% triamcinolone acetonide paste). Budesonide or beclomethasone inhalers (one puff three to four times daily) provide an alternative method of delivering local corticosteroid to the inflamed mucosal surfaces. Short courses of high-dose oral prednisolone may be needed for severe oral disease. Strict eye care to reduce secondary infection and scarring includes saline washes for removal of crusts, local antibiotics , and frequent debridement of tarsal and bulbar conjunctival adherences .

Specific Investigation

  • Histology/immunofluorescence

EM is a clinical diagnosis. Histology, with direct immunofluorescence, can be useful in atypical cases to exclude other bullous diseases that present with oral manifestations, such as pemphigus vulgaris or cicatricial pemphigoid.

Investigations directed at determining the underlying trigger factors include culture or serologic testing for HSV or other infections, especially M. pneumoniae, as indicated by clinical findings.

First-Line Therapies

  • Antivirals (aciclovir, valaciclovir, ganciclovir)

A
  • Macrolide antibiotics for mycoplasma pneumoniae -induced EM major

C

Recurrent erythema multiforme: clinical features and treatment in a large series of patients

Schofield JK, Tatnall FM, Leigh IM. Br J Dermatol 1993; 128: 542–5.

A review of 65 patients with recurrent EM: 71% had episodes triggered by HSV infection. Treatment with standard doses of aciclovir for HSV was relatively disappointing; continuous aciclovir 400 mg twice daily for 6 months was more effective, with remission in some responders. Some patients responded to dapsone, antimalarials, azathioprine (10 of 11), and human immunoglobulin.

A double-blind, placebo-controlled trial of continuous aciclovir therapy in recurrent erythema multiforme

Tatnall FM, Schofield JK, et al. Br J Dermatol 1995; 132: 267–70.

Aciclovir 400 mg twice daily for 6 months suppressed EM in seven of 11 patients (including one with apparently idiopathic EM). Two patients went into complete remission.

A therapeutic trial of aciclovir is justified even when clinical evidence of HSV is lacking. Aciclovir 400 mg twice daily can be administered for 6 months to 2 years because it has a good long-term safety profile. It is ineffective in an acute episode once the herpetic lesion or EM eruption has developed. Recurrence is usual after stopping the drug.

Clinical and histologic features of Mycoplasma pneumoniae -related erythema multiforme: a single-center series of 33 cases compared with 100 cases induced by other causes

Amode R, Ingen-Housz-Oro S, Ortonne N, et al. J Am Acad Dermatol 2018; 79: 110–7.

MP-induced EM have more mucous membrane lesions, more atypical targets, and more respiratory tract sequelae; they have to be treated by macrolide antibiotics.

Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007

Wetter DA, Davis MD. J Am Acad Dermatol 2010; 62: 45–53.

Of 48 patients, HSV was responsible in 11 (23%); the cause remained unknown in 28 (58%). Systemic corticosteroids were used in most patients. Sixteen of 33 patients receiving continuous antiviral treatment had either partial or complete disease suppression. Mycophenolate mofetil provided partial or complete response in six of eight patients.

Second-Line Therapies

  • Dapsone

C
  • Azathioprine

C
  • Thalidomide & lenalidomide

B
  • Potassium iodide

C
Oral EM
  • Topical corticosteroid

B
  • Levamisole

B
  • Systemic corticosteroid

D

Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme

Farthing PM, Maragou P, Coates M, et al. J Oral Pathol Med 1995; 24: 9–13.

In this series of 82 patients with typical cutaneous EM, 70% had oral mucosal involvement. Five patients with resistant disease were controlled with azathioprine 100–150 mg daily.

Azathioprine therapy in the management of persistent erythema multiforme

Jones RR. Br J Dermatol 1981; 105: 465–7.

Azathioprine 100–150 mg daily was effective in two patients and permitted reduction of the corticosteroid dosage.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here